{"paper_id":"dd1eac5d-bce6-4076-87d5-a839dc8ef047","body_text":"Abstract\nObjective\nTo assess the efficacy and safety of Sanjie Analgesic Capsule (SAC) in Chinese patients with endometriosis-associated pain.\nMethods\nThis was a multicenter, randomized, double-blind, placebo-controlled trial conducted at 15 centers between November 2013 and July 2017 in China. Eligible 323 patients with endometriosis were randomized at a 3:1 ratio to the SAC group (241 cases) and placebo group (82 cases) by stratified block randomization. Patients in the SAC or placebo groups were given SAC or placebo 1.6 g 3 times per day, orally, respectively since the first day of menstruation for 3 consecutive menstrual cycles. The primary endpoint was clinical response to dysmenorrhea evaluated using a 10-point Visual Analogue Scale at 3 and 6 months. The secondary endpoint was the pain score evaluated by VAS (chronic pelvic pain, defecation pain, and dyspareunia) at 3 and 6 months, and the pain recurrence rate at 6 months. Adverse events (AEs) were recorded during the study.\nResults\nA total of 241 women were included in the SAC group, and 82 were in the placebo group. Among these women, 217 (90.0%) and 71 (86.6%) completed the intervention, respectively. At 3 months, overall response rate (ORR) was significantly higher in women administered SAC (80.1%) compared with those who received a placebo (30.5%, P<0.01). Six months after treatment, the ORR for dysmenorrhea was 62.7% in the SAC group and 31.7% in the placebo group (P<0.01). Chronic pelvic pain and defecation pain were significantly improved by SAC compared with placebo (both P<0.05). The incidence rates of total AEs events in the SAC and placebo groups were 6.6% and 9.8%, respectively, and no significant difference was shown between the two groups (P=0.339).\nConclusion\nSAC is well-tolerated and may improve dysmenorrhea in women with endometriosis-associated pain. (Trial registration: ClinicalTrials.gov, No. NCT02031523)\nSimilar content being viewed by others\nReferences\nTaylor HS, Kotlyar AM, Flores VA. Endometriosis is a chronic systemic disease: clinical challenges and novel innovations. Lancet 2021;397:839–852.\nTaylor HS, Adamson GD, Diamond MP, Goldstein SR, Horne AW, Missmer SA, et al. An evidence-based approach to assessing surgical versus clinical diagnosis of symptomatic endometriosis. Int J Gynaecol Obstet 2018;142:131–142.\nEid S, Loukas M, Tubbs RS. Clinical anatomy of pelvic pain in women: a gynecological perspective. Clin Anat 2019;32:151–155.\nZondervan KT, Becker CM, Missmer SA. Endometriosis. N Engl J Med 2020;382:1244–1256.\nCasper RF. Progestin-only pills may be a better first-line treatment for endometriosis than combined estrogen-progestin contraceptive pills. Fertil Steril 2017;107:533–536.\nBuggio L, Somigliana E, Barbara G, Frattaruolo MP, Vercellini P. Oral and depot progestin therapy for endometriosis: towards a personalized medicine. Expert Opin Pharmacother 2017;18:1569–1581.\nBrown J, Crawford TJ, Allen C, Hopewell S, Prentice A. Nonsteroidal anti-inflammatory drugs for pain in women with endometriosis. Cochrane Database Syst Rev 2017;1:CD004753.\nOladosu FA, Tu FF, Hellman KM. Nonsteroidal antiinflammatory drug resistance in dysmenorrhea: epidemiology, causes, and treatment. Am J Obstet Gynecol 2018;218:390–400.\nHorne AW, Missmer SA. Pathophysiology, diagnosis, and management of endometriosis. BMJ 2022;379:e070750.\nSaunders PTK, Horne AW. Endometriosis: etiology, pathobiology, and therapeutic prospects. Cell 2021;184:2807–2824.\nYan H, Shi J, Li X, Dai Y, Wu Y, Zhang J, et al. Oral gonadotropin-releasing hormone antagonists for treating endometriosis-associated pain: a systematic review and network meta-analysis. Fertil Steril 2022;118:1102–1116.\nPerricos A, Wenzl R. Efficacy of elagolix in the treatment of endometriosis. Expert Opin Pharmacother 2017;18:1391–1397.\nZhao RH, Liu Y, Lu D, Wu Y, Wang XY, Li WL, et al. Chinese medicine sequential therapy improves pregnancy outcomes after surgery for endometriosis-associated infertility: a multicenter randomized double-blind placebo parallel controlled clinical trial. Chin J Integr Med 2020;26:92–99.\nDai Y, Li X, Shi J, Leng J. A review of the risk factors, genetics and treatment of endometriosis in Chinese women: a comparative update. Reprod Health 2018;15:82.\nGuo R, Yi Z, Wang Y, Wang L. Network pharmacology and experimental validation to explore the potential mechanism of Sanjie Zhentong Capsule in endometriosis treatment. Front Endocrinol (Lausanne) 2023;14:1110995.\nZou J, Guan Z, Zhang WY, Xiao W, Li YL. Beneficial effects of the Chinese herbal medicine Sanjie Zhentong Capsule on experimental endometriosis in rats. Chin J Nat Med 2013;11:666–672.\nHuang ZH. The clinical application of Sanjie Zhentong Capsules after laparoscopic surgery in the pelvic endometriosis. Chin J Integr Tradit West Med (Chin) 2007;27:748.\nKowanetz M, Zou W, Gettinger SN, Koeppen H, Kockx M, Schmid P, et al. Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti-PD-L1). Proc Natl Acad Sci U S A 2018;115:E10119–E10126.\nCooperative Group of Endometriosis, Chinese Society of Obstetrics and Gynecology, Chinese Medical Association. Norms for diagnosis and treatment of endometriosis. Chin J Obstetr Gynecol (Chin) 2007;42:645–648.\nChen I, Veth VB, Choudhry AJ, Murji A, Zakhari A, Black AY, et al. Pre- and postsurgical medical therapy for endometriosis surgery. Cochrane Database Syst Rev 2020;11:CD003678.\nSong Nan, Wang Yanyan, Leng Jinhua. Effect of Sanjie Analgesia Capsule on dysmenorrhea in endometriosis and adenomyosis. Chin J Appl Gynecol Obstetr (Chin) 2010;26:222–223.\nShang Y, Zhao X, Li H, Xu Y, Zhao H, Zhao L. Clinical effect of rehabilitation new fluid combined with Sanjie Analgesic Capsules in the treatment of granulomatous mastitis and thyroiditis and impact on immune indexes of patients. Altern Ther Health Med 2023:AT9209.\nHerman MC, Mak N, Geomini PM, Winkens B, Mol BW, Bongers MY. Is the Pictorial Blood Loss Assessment Chart (PBAC) score associated with treatment outcome after endometrial ablation for heavy menstrual bleeding? A cohort study. BJOG 2017;124:277–282.\nChen CX, Carpenter JS, Ofner S, LaPradd M, Fortenberry JD. Dysmenorrhea symptom-based phenotypes: a replication and extension study. Nurs Res 2021;70:24–33.\nHarada T, Momoeda M, Taketani Y, Hoshiai H, Terakawa N. Low-dose oral contraceptive pill for dysmenorrhea associated with endometriosis: a placebo-controlled, double-blind, randomized trial. Fertil Steril 2008;90:1583–1588.\nDavis L, Kennedy SS, Moore J, Prentice A. Oral contraceptives for pain associated with endometriosis. Cochrane Database Syst Rev 2007;3:CD001019.\nSun Y, Yang J. A bioinformatics investigation into the pharmacological mechanisms of the effect of Fufang Danshen on pain based on methodologies of network pharmacology. Sci Rep 2019;9:5913.\nZhang Z, Zhang Y, Gao M, Cui X, Yang Y, van Duijn B, et al. Steamed Panax notoginseng attenuates anemia in mice with blood deficiency syndrome via regulating hematopoietic factors and JAK-STAT pathway. Front Pharmacol 2019;10:1578.\nXiong Y, Chen L, Hu Y, Cui X. Uncovering active constituents responsible for different activities of raw and steamed Panax notoginseng roots. Front Pharmacol 2017;8:745.\nJiang Y, Zhang G, Yan D, Yang H, Ye Z, Ma T. Bioactivity-guided fractionation of the traditional Chinese medicine Resina Draconis reveals loureirin B as a PAI-1 inhibitor. Evid Based Complement Alternat Med 2017;2017:9425963.\nShi S, Zhao Q, Ke C, Long S, Zhang F, Zhang X, et al. Loureirin B exerts its immunosuppressive effects by inhibiting STIM1/Orai1 and KV1.3 channels. Front Pharmacol 2021;12:685092.\nNile SH, Su J, Wu D, Wang L, Hu J, Sieniawska E, et al. Fritillaria thunbergii Miq. (Zhe Beimu): a review on its traditional uses, phytochemical profile and pharmacological properties. Food Chem Toxicol 2021;153:112289.\nToh MF, Mendonca E, Eddie SL, Endsley MP, Lantvit DD, Petukhov PA, et al. Kaempferol exhibits progestogenic effects in ovariectomized rats. J Steroids Horm Sci 2014;5:136.\nJinnouchi M, Miyahara T, Suzuki Y. Coix seed consumption affects the gut microbiota and the peripheral lymphocyte subset profiles of healthy male adults. Nutrients 2021;13:4079.\nAuthor information\nAuthors and Affiliations\nContributions\nLang JH contributed to study design, data collection and analysis, statistical analysis, manuscript drafting supervision and critical revision of the manuscript. Duan H, Guan Z, Zhou YF, Qu H, Xu KH, Zhang SF, Zhang Q, Wang X and Lin KQ contributed to study design, data collection and analysis. All authors have read and approved the final manuscript for publication.\nCorresponding author\nEthics declarations\nThe authors declare that they have no conflicts of interest. This study was supported by Jiangsu Kanion Pharmaceutical Co., Ltd, China. Jiangsu Kanion Pharmaceutical Co., Ltd. did not participate in the research related work such as design and data analysis.\nElectronic supplementary material\nRights and permissions\nAbout this article\nCite this article\nLeng, Jh., Duan, H., Guan, Z. et al. Efficacy and Safety of Sanjie Analgesic Capsule in Patients with Endometriosis-Associated Pain: A Multicenter, 3:1 Randomized, Double-Blind, Placebo-Controlled Trial. Chin. J. Integr. Med. 30, 780–787 (2024). https://doi.org/10.1007/s11655-024-3756-y\nAccepted:\nPublished:\nVersion of record:\nIssue date:\nDOI: https://doi.org/10.1007/s11655-024-3756-y","source_license":"CC0","license_restricted":false}